(TheNewswire)
-
Successful completion of Phase 1Clinical Trials
-
MindBio remains the only organizationin the world to have successfully obtained government approvals for adoctor to prescribe LSD (lysergic acid diethylamide) to patients totake the drug unsupervised in the community in the same way they wouldtake any other medicine
-
Phase 1 clinical trial report andsafety data is being analyzed and will be announced shortly
-
Phase 2 clinical trials currently indevelopment
-
MindBio spin-out plans progressing asscheduled
Vancouver, British Columbia – TheNewswire - May 3 rd , 2022 –Blackhawk Growth Corp. (CSE:BLR ) ; (CNSX:BLR.CN); (OTC:BLRZF); ( Frankfurt:0JJ) (the“ Company ” or “ Blackhawk ”) is pleased to report thatMindBio Therapeutics (“ MindBio ”) has completed its 12 month Phase 1clinical trial microdosing LSD in 80 healthy participants.
MindBio is developing a microdosing regimen using LSDto treat mental health disorders such as depression. To get thesenovel treatments to market, MindBio needs to prove safety and efficacyof the treatment using a rigorous clinical trial process.
The Phase 1 Clinical Trial is the largest safety studyof its kind that has ever been completed under a randomized, doubleblind placebo controlled discipline, the results of which will supportdevelopment of MindBio’s intellectual property and progressiontowards commercialization of treatments for mental healthconditions.
MindBio is looking forward to analyzing the data fromthe Phase 1 clinical trial to further inform its planned Phase 2clinical trials.
MindBio is working towards creating a safe andeffective microdosing regimen using psychedelics that can beprescribed by doctors to patients in the primary health caresystem . In larger doses, LSD is ahallucinogenic drug that substantially changes cognition, thinking,mood and perception, however in much smaller “microdoses”, themedicine is subperceptual, meaning that patients can take the drugwithout noticing its hallucinogenic effects, but still receive themedicinal benefit and get on with their normal day.
MindBio is working towards becoming the first to marketby commercializing a microdosing regimen with substantial potentialglobal mental health care benefits.
“We are proud of the incredible work of ourscientific team and the completion of this great milestone as we headtowards developing game-changing treatments for mental healthconditions,” said Frederick Pels, CEO of Blackhawk.
MindBio is continuing to progress towards itspreviously announced spin out which it anticipates completingfollowing receipt of all necessary approvals including approval by theshareholders of Blackhawk. The spin out of MindBio is expected tocreate significant shareholder value as each Blackhawk shareholderwill receive shares in MindBio upon completion of the spin out.
About Blackhawk Growth
Blackhawk is an investment holding company looking tocreate substantial value for its shareholders through the acquisitionand development of high growth companies. It has focused itsinvestments in the health, cannabis and cannabidiol industries in bothCanada and the United States. Its portfolio of companies includes SacPharma, LeichtMind Clinics, Noble Hemp, Spaced Food, NuWave Foods,MindBio Therapeutics, Digital Mind Therapeutics, Blum Distributors Ltdas well as an equity position in Gaia Grow Corp (CSE:GAIA).
The Company diligently posts updates through videosfrom the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A
Please join the conversation on our Blackhawk groupsupporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com .
For further information please contact:
Frederick Pels, Chief ExecutiveOfficer
(403)-991-7737
fred@ blackhawkgrowth.com
Cautionary NoteRegarding Forward-Looking Statement
All statements in this pressrelease, other than statements of historical fact, are “forward-looking information”with respect to the Company within the meaning of applicablesecurities laws, including with respect to transaction and futureoperations of MindBio Therapeutics Pty Ltd. The Company providesforward-looking statements for the purpose of conveying informationabout current expectations and plans relating to the future andreaders are cautioned that such statements may not be appropriate forother purposes. By its nature, this information is subject to inherentrisks and uncertainties that may be general or specific and which giverise to the possibility that expectations, forecasts, predictions,projections or conclusions will not prove to be accurate, thatassumptions may not be correct and that objectives, strategic goalsand priorities will not be achieved. These risks and uncertaintiesinclude but are not limited those identified and reported in theCompany’s public filings under the Company’s SEDAR profile atwww.sedar.com. Although the Company has attempted to identifyimportant factors that could cause actual actions, events or resultsto differ materially from those described in forward-lookinginformation, there may be other factors that cause actions, events orresults not to be as anticipated, estimated or intended. There can beno assurance that such information will prove to be accurate as actualresults and future events could differ materially from thoseanticipated in such statements. The Company disclaims any intention orobligation to update or revise any forward-looking information,whether as a result of new information, future events or otherwiseunless required by law.
Copyright (c) 2022 TheNewswire - All rights reserved.